Quick Answer
Regen BioPharma Inc reported Net Income Loss of -$1.27 million for the year ending 2025.
- Regen BioPharma Inc showed a decrease of -90.7% in Net Income Loss from 2024 to 2025.
- This data is from Regen BioPharma Inc's annual report (Form 10-K), filed with the SEC on December 30, 2025.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: -$186.2 thousand | Q2 2014: -$166.0 thousand | Q3 2014: -$194.6 thousand | Q4 2014: -$219.2 thousand | Q1 2015: -$8.81 million | Q2 2015: -$1.56 million | Q3 2015: -$600.7 thousand | Q4 2015: -$1.86 million | Q1 2016: -$1.09 million | Q2 2016: -$2.36 million | Q4 2016: -$2.52 million | Q1 2017: -$1.31 million | Q2 2017: -$2.62 million | Q4 2017: -$2.79 million | Q1 2018: -$1.13 million | Q2 2018: -$107.6 thousand | Q4 2018: $245.1 thousand | Q1 2019: -$333.2 thousand | Q2 2019: -$4.41 million | Q4 2019: $3.08 million | Q1 2020: -$4.08 million | Q2 2020: $3.21 million | Q4 2020: $1.67 million | Q1 2021: $442.2 thousand | Q2 2021: -$7.49 million | Q4 2021: $2.64 million | Q1 2022: -$67.08 million | Q2 2022: $66.96 million | Q4 2022: $1.64 million | Q1 2023: -$55.0 thousand | Q2 2023: -$99.2 thousand | Q4 2023: -$144.9 thousand | Q1 2024: -$122.5 thousand | Q2 2024: -$130.1 thousand | Q4 2024: -$515.4 thousand | Q1 2025: -$19.4 thousand | Q2 2025: -$167.3 thousand | Q4 2025: -$967.9 thousand.
- Over the full 13 years of available data (2013 to 2025), Regen BioPharma Inc's Net Income Loss has declined by 259.0%.
- Historical annual values: Fiscal year 2025: -$1.27 million | Fiscal year 2024: -$668.3 thousand | Fiscal year 2023: $1.16 million | Fiscal year 2022: $2.44 million | Fiscal year 2021: -$6.77 million | Fiscal year 2020: $3.41 million | Fiscal year 2019: -$2.62 million | Fiscal year 2018: -$4.72 million | Fiscal year 2017: -$5.84 million | Fiscal year 2016: -$7.75 million | Fiscal year 2015: -$11.20 million | Fiscal year 2014: -$756.4 thousand | Fiscal year 2013: -$355.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: